These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Uncoupling the Oncogenic Engine. Schambach A; Schott JW; Morgan MA Cancer Res; 2017 Nov; 77(22):6060-6064. PubMed ID: 29097608 [TBL] [Abstract][Full Text] [Related]
4. The impact of oncogenic RAS on redox balance and implications for cancer development. Lim JKM; Leprivier G Cell Death Dis; 2019 Dec; 10(12):955. PubMed ID: 31852884 [TBL] [Abstract][Full Text] [Related]
5. Oncogenic signaling pathways and deregulated target genes. Schäfer R; Schramme A; Tchernitsa OI; Sers C Recent Results Cancer Res; 2007; 176():7-24. PubMed ID: 17607912 [TBL] [Abstract][Full Text] [Related]
6. New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling. Erickson KE; Rukhlenko OS; Posner RG; Hlavacek WS; Kholodenko BN Semin Cancer Biol; 2019 Feb; 54():162-173. PubMed ID: 29518522 [TBL] [Abstract][Full Text] [Related]
7. Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers. Mattox TE; Chen X; Maxuitenko YY; Keeton AB; Piazza GA Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31878223 [TBL] [Abstract][Full Text] [Related]
8. Blocking oncogenic Ras signaling for cancer therapy. Adjei AA J Natl Cancer Inst; 2001 Jul; 93(14):1062-74. PubMed ID: 11459867 [TBL] [Abstract][Full Text] [Related]
9. RAS-mediated oncogenic signaling pathways in human malignancies. Khan AQ; Kuttikrishnan S; Siveen KS; Prabhu KS; Shanmugakonar M; Al-Naemi HA; Haris M; Dermime S; Uddin S Semin Cancer Biol; 2019 Feb; 54():1-13. PubMed ID: 29524560 [TBL] [Abstract][Full Text] [Related]
10. The impact of the regulatory design on the response of epidermal growth factor receptor-mediated signal transduction towards oncogenic mutations. Wolf J; Dronov S; Tobin F; Goryanin I FEBS J; 2007 Nov; 274(21):5505-17. PubMed ID: 17916191 [TBL] [Abstract][Full Text] [Related]
11. Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. Hafner C; Toll A; Fernández-Casado A; Earl J; Marqués M; Acquadro F; Méndez-Pertuz M; Urioste M; Malats N; Burns JE; Knowles MA; Cigudosa JC; Hartmann A; Vogt T; Landthaler M; Pujol RM; Real FX Proc Natl Acad Sci U S A; 2010 Nov; 107(48):20780-5. PubMed ID: 21078999 [TBL] [Abstract][Full Text] [Related]
12. [RAS mutations at the molecular tumor conference]. Schäfer R Pathologe; 2019 Dec; 40(Suppl 3):355-359. PubMed ID: 31754788 [TBL] [Abstract][Full Text] [Related]
13. [Impact of prenylation inhibition on RAS mutant tumors in preclinical studies]. Baranyi M; Molnár E; Rittler D; Hegedûs B; Tímár J Magy Onkol; 2019 Dec; 63(4):320-329. PubMed ID: 31821387 [TBL] [Abstract][Full Text] [Related]
14. Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras. Wandler A; Shannon K Cold Spring Harb Perspect Med; 2018 Apr; 8(4):. PubMed ID: 28778967 [No Abstract] [Full Text] [Related]
15. Oncogenic Ras Isoforms Signaling Specificity at the Membrane. Nussinov R; Tsai CJ; Jang H Cancer Res; 2018 Feb; 78(3):593-602. PubMed ID: 29273632 [TBL] [Abstract][Full Text] [Related]
16. Recapitulation of ras oncogene mutations in breast cancer. Stamatakos M; Stefanaki C; Kontzoglou K; Masouridi S; Sakorafas G; Safioleas M Onkologie; 2010; 33(10):540-4. PubMed ID: 20926903 [TBL] [Abstract][Full Text] [Related]
17. Activated K-RAS and its effect on morphological appearance. Kiyokawa E; Minato H J Biochem; 2014 Sep; 156(3):137-45. PubMed ID: 24958732 [TBL] [Abstract][Full Text] [Related]